Cardiologists Perform First TAVR of Its Kind by Anchoring Valve to Crushed Stent

Why It Matters

The case proves a feasible bridge for high‑risk patients with pure native AR lacking calcification, expanding TAVR’s therapeutic envelope while underscoring the urgent need for dedicated AR devices.

Key Takeaways

• First ATLAS TAVR anchors valve to crushed stent.
• Targets non‑calcified aortic regurgitation in high‑risk patients.
• Non‑coronary cusp chosen to preserve coronary flow.
• Palmaz stent provides robust anchoring, not vascular plugs.
• Success suggests bridge until dedicated AR TAVR devices emerge.

Pulse Analysis

Transcatheter aortic valve replacement has transformed treatment for calcified aortic stenosis, yet pure native aortic regurgitation (AR) remains a frontier because the lack of leaflet calcification offers little for conventional valve anchoring. Clinicians have relied on surgical repair or high‑risk open procedures, leaving a vulnerable cohort without minimally invasive options. The ATLAS technique directly addresses this gap by creating a mechanical foothold—crushing a sturdy Palmaz stent against the left ventricular outflow tract—thereby securing the valve without depending on calcific support.

The procedural nuance lies in selecting the non‑coronary cusp, which eliminates the risk of obstructing coronary ostia and provides optimal fluoroscopic visibility. By deploying the stent via right axillary and femoral access, then expanding the Sapien 3 valve within the crushed scaffold, operators achieved stable fixation confirmed by fluoroscopy and computed tomography. This hybrid approach, while technically demanding, demonstrates that existing TAVR platforms can be adapted for AR when paired with innovative anchoring strategies, though it does not replace the need for devices engineered specifically for non‑calcified anatomy.

Industry implications are significant. The successful ATLAS case signals to device manufacturers that a market exists for dedicated AR transcatheter valves capable of reproducible leaflet engagement and large annular accommodation. Until such platforms mature, hybrid techniques will likely serve as interim solutions for select high‑risk patients, driving further clinical research and regulatory interest. Ultimately, the evolution of AR‑focused TAVR technology could broaden the procedure’s applicability, reduce surgical morbidity, and reshape heart‑team decision‑making.